Optimize Patient Outcomes by Improving Pre-Analytics

Presented by

Dr. David Hicks, Prof & Dir of IHC-ISH Laboratory & Breast Subspecialty Service, University of Rochester Medical Center

About this talk

With the increasing emphasis on precision medicine in oncology and the need for biomarker testing, pathologists and the pathology community are in the center of the patient's tissue journey. As guardians and stewards of the tissue, pathologists are responsible for ensuring the quality of samples used for accurate diagnosis and biomarker testing. Preanalytics - the collection, handling and processing of clinical biospecimens - are critically important but rigor around the control of factors that adversely affect biospecimens is lacking. This presentation will introduce the tissue optimization and pre-analytic standardization program developed by APPIA, the Anatomic Pathology Patient Interest Association, a non-profit consortium with membership from Agilent, Leica Biosystems, Roche and Sakura Finetek. The mission of APPIA is to advance patient safety, quality, standards and accessibility of care in anatomic pathology. This presentation will provide a better understanding of how the lack of standardization of pre-analytic factors has the potential to negatively impact the quality of the tissue specimen for downstream diagnostic and molecular testing. Examples of best practices to help optimize tissue preservation and quality and how these can be implemented in clinical practice will be discussed.

Related topics:

More from this channel

Upcoming talks (0)
On-demand talks (53)
Subscribers (6832)
This series is brought to you by Roche. We are committed to providing you with educational content, from key opinion leaders, related to personalized diagnostics. We aim to ensure on ongoing conversation is taking place in this evolving area of healthcare. Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices. The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.